14 Jan 2021 --- Chr. Hansen is on track to fulfill its 2025 strategy following its Q1 2020/21 results, which revealed overall organic sales growth of 10 percent. However, there are temporary capacity constraints in its human milk oligosaccharide (HMO) business, which is set to impact FY21 revenues negatively.
